Patient Satisfaction and Safety With Aesthetic OnabotulinumtoxinA After At Least 5 Years

Almeida, Ada Trindade de; Carruthers, Jean; Cox, Sue Ellen; Goldman, Mitchel P.; Wheeler, Sarah; Gallagher, Conor J.

doi:10.1097/dss.0000000000000275

Cited by 39 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective medical chart review of 194 patients who received a total of 4402 onabotulinumtoxinA treatments to glabellar lines over a mean of 9.1 years demonstrated sustained patient and physician satisfaction. 40 Greater perceived benefits were reported in patients treated for longer periods.…”

Section: Evolving Concepts In Facial Agingmentioning

confidence: 99%

Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A—Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations

Sundaram¹,

Liew²,

Signorini³

et al. 2016

Plastic &Amp; Reconstructive Surgery

112

View full text Add to dashboard Cite

show abstract

Section: Evolving Concepts In Facial Agingmentioning

confidence: 99%

Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A—Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations

Sundaram¹,

Liew²,

Signorini³

et al. 2016

Plastic &Amp; Reconstructive Surgery

112

View full text Add to dashboard Cite

show abstract

“…23 Separate analysis of the same data set demonstrated sustained patient and physician satisfaction with repeated treatment. 24 Patients reported greater reduction in their perceived age as they received treatments for longer periods. 23 …”

Section: Evolving Paradigms In Patient Assessment and Treatment Planningmentioning

confidence: 99%

Global Aesthetics Consensus

Sundaram¹,

Signorini²,

Liew³

et al. 2016

Plastic and Reconstructive Surgery

164

View full text Add to dashboard Cite

Background:Botulinum toxin type A injection remains the leading nonsurgical cosmetic procedure worldwide, with a high rate of efficacy and patient satisfaction.Methods:A multinational, multidisciplinary group of plastic surgeons and dermatologists convened the Global Aesthetics Consensus Group to develop updated consensus recommendations with a worldwide perspective for botulinum toxin and hyaluronic acid fillers. This publication on botulinum toxin type A considers advances in facial analysis, injection techniques, and avoidance and management of complications.Results:Use of botulinum toxin has evolved from the upper face to also encompass the lower face, neck, and midface. The Global Aesthetics Consensus Group emphasizes an integrative, diagnostic approach. Injection dosage and placement are based on analysis of target muscles in the context of adjacent ones and associated soft and hard tissues. The indication for selection of botulinum toxin as a primary intervention is that excessive muscular contraction is the primary etiology of the facial disharmony to be addressed. Global Aesthetics Consensus Group recommendations demonstrate a paradigm shift toward neuromodulation rather than paralysis, including lower dosing of the upper face, more frequent combination treatment with hyaluronic acid fillers, and intracutaneous injection where indicated to limit depth and degree of action.Conclusions:The accumulation of clinical evidence and experience with botulinum toxin has led to refinements in treatment planning and implementation. The Global Aesthetics Consensus Group advocates an etiology-driven, patient-tailored approach, to enable achievement of optimal efficacy and safety in patient populations that are rapidly diversifying with respect to ethnicity, gender, and age.CLINCAL QUESTION/LEVEL OF EVIDENCE:Therapeutic, V.

show abstract

“…There is no reason to believe that safety, efficacy, or patient satisfaction is likely to decline over time. Indeed, in a recent long‐term analysis of 194 individuals treated with onabotulinumtoxinA for glabellar lines for a mean of 9.1 years, 92.3% reported being mostly or very satisfied and 89.7% said they looked younger …”

Section: Discussionmentioning

confidence: 99%

Full‐face treatment with onabotulinumtoxinA: Results from a single‐center study

D'Emilio¹,

Rosati²

2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Botulinum toxin type A injection is a common aesthetic treatment that can be used alone or in combination to rejuvenate the entire face and neck. Objectives To assess the safety and efficacy of a full‐face approach with botulinum toxin type A. Methods This was a single‐center, retrospective review of data from 189 patients receiving full‐face and neck treatment with onabotulinumtoxinA in the following areas: glabellar lines, crow's feet lines, forehead lines, bunny lines, sagging nasal tip, gummy smile, marionette lines, mentalis, masseter, and lateral/anterior platysma. Results The mean age was 56.6 ± 9.2 years, and 94.7% were women (n = 179). Patients received a total of 394 full‐face treatments (mean: 2.1 per person; range 1‐7). The mean quantity of onabotulinumtoxinA injected was 113.8 ± 17.6 units per treatment (range: 50‐180 units). The most frequently injected areas were the glabella/crow's feet/forehead (n = 383; 97.2%), platysma (n = 378; 95.9%), bunny lines (n = 283; 71.8%), and chin (n = 120; 30.5%). Six patients (3.2%) experienced complications: five cases of unwanted diffusion from the mentalis into the depressor labii inferioris and one case of right eyelid ptosis after injection in the upper third. All were minor and none appeared to be related to overall dose. Conclusions Full‐face and neck treatment with onabotulinumtoxinA can be performed without substantial safety concerns, often leading to excellent results. This approach may become increasingly prevalent in the coming years.

show abstract

Patient Satisfaction and Safety With Aesthetic OnabotulinumtoxinA After At Least 5 Years

Abstract: Continuous treatment with onabotulinumtoxinA for a mean of 9.1 years was associated with very high patient satisfaction.

Cited by 39 publications

References 34 publications

Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A—Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations

Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A—Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations

Global Aesthetics Consensus

Full‐face treatment with onabotulinumtoxinA: Results from a single‐center study

Contact Info

Product

Resources

About